【用戶】Tsun-Jung Zho
【年級】國二下
【評論內容】(B) Flumazenil － Competitive BZD AntagonistPS. Flumenizil is 「BZD-Receptor Antagonist」─ Zero Modulators
【用戶】Swear
【年級】幼稚園下
【評論內容】Omalizumab, a humanised monoclonal antibody IgG1, is a treatment for moderate to severe persistent allergic asthma and Chronic Idiopathic Urticaria (CIU) in appropriate patients.
【用戶】Tsun-Jung Zho
【年級】國二下
【評論內容】(B) Flumazenil － Competitive BZD AntagonistPS. Flumenizil is 「BZD-Receptor Antagonist」─ Zero Modulators
【用戶】Swear
【年級】幼稚園下
【評論內容】Omalizumab, a humanised monoclonal antibody IgG1, is a treatment for moderate to severe persistent allergic asthma and Chronic Idiopathic Urticaria (CIU) in appropriate patients.
【用戶】Tsun-Jung Zho
【年級】國二下
【評論內容】(B) Flumazenil － Competitive BZD AntagonistPS. Flumenizil is 「BZD-Receptor Antagonist」─ Zero Modulators
【用戶】Swear
【年級】幼稚園下
【評論內容】Omalizumab, a humanised monoclonal antibody IgG1, is a treatment for moderate to severe persistent allergic asthma and Chronic Idiopathic Urticaria (CIU) in appropriate patients.
【用戶】Tsun-Jung Zho
【年級】國二下
【評論內容】(B) Flumazenil － Competitive BZD AntagonistPS. Flumenizil is 「BZD-Receptor Antagonist」─ Zero Modulators
【用戶】Swear
【年級】幼稚園下
【評論內容】Omalizumab, a humanised monoclonal antibody IgG1, is a treatment for moderate to severe persistent allergic asthma and Chronic Idiopathic Urticaria (CIU) in appropriate patients.
【用戶】Swear
【年級】幼兒園下
【評論內容】Omalizumab, a humanised monoclonal antibody IgG1, is a treatment for moderate to severe persistent allergic asthma and Chronic Idiopathic Urticaria (CIU) in appropriate patients.
【用戶】考運旺旺旺
【年級】高三上
【評論內容】99-1-39BZD 正向 讓Cl-流入 (抑制、鎮靜)Flumazenil 零向 不會使Cl-流進或流出β-carcoline 負向 讓Cl-流出 (興奮、增加焦慮，引起恐慌，可改善記憶)